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RESUMEN
El descubrimiento de nuevas dianas de fármacos se enfoca cada vez más a las
secuencias genómicas, a los transcritos RNA o a los análisis de proteínas, pero las
expectativas para identificar un mayor número de nuevas estructuras para la investi-
gación farmacéutica no han sido cumplidas durante la pasada década. En esta situa-
ción, parece importante adquirir información más detallada acerca de las condicio-
nes moleculares en enfermos durante infecciones, enfermedades malignas, alergias,
enfermedades reumáticas o diabetes, en lugar de guiarse preferentemente por el com-
portamiento de sistemas de cultivos celulares o modelos animales. Tales sistemas pue-
den no poseer el mismo comportamiento regulador que el organismo humano.
La información molecular puede ser obtenida eficientemente a partir de cé-
lulas humanas por citometría de flujo de imagen o química, llevando a cabo aná-
lisis simultáneos multiparamétricos de sistemas celulares (citomas) de donde emer-
gen las enfermedades como consecuencia de procesos celulares moleculares
aberrantes. La citómica, como análisis molecular multiparamétrico de células ais-
ladas, en combinación con conocimientos exhaustivos bioinformáticos, propor-
ciona la terapia relacionada con predicciones individualizadas en el curso de la
enfermedad en pacientes, sobre la base de pautas o modelos bioparamétricos dis-
criminatorios. Estos modelos son importantes para estudiar i) la ingeniería mole-
cular de las vías metabólicas de la enfermedad, ii) el descubrimiento de nuevas
dianas de fármacos, como también iii) la medicina clínica de cada día.
La propuesta de un proyecto de citoma humano presenta la posibilidad de
avanzar sistemáticamente en este tema que presenta tan amplias aplicaciones.
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SUMMARY
The discovery of new drug targets is increasingly conceptualized from ge-
nome sequences, RNA transcripts or proteome analysis but the expectations to
identify an increased numbers of new target structures for pharmaceutical rese-
arch have not fulfilled during the last decade. It seems in this situation impor-
tant to acquire more detailed information on the molecular conditions in disea-
sed humans like during infections, malignancies, allergies, rheumatic diseases
or diabetes instead of being preferentially guided by the behavior of cell cultu-
res or animal model systems. Such systems may ultimately not possess the same
regulatory behavior as the human organism. 
Molecular information can be efficiently collected from human single cells
by flow, image or chemical cytometry performing simultaneous multiparame-
tric analysis of cell systems (cytomes) from where diseases emerge as conse-
quence of aberrant molecular cell processes. Cytomics, as multiparametric mo-
lecular single cell analysis in combination with exhaustive bioinformatic
knowledge extraction provide therapy related individualized disease course pre-
dictions for patients on the basis of characteristically discriminatory biopara-
meter patterns. These patterns are of importance i) for the molecular reverse en-
gineering of disease pathways, ii) for the discovery of new drug targets as well
as iii) for everyday clinical medicine. 
The proposal of a human cytome project has the potential to systematically
advance this widely applicable approach. 
1. INTRODUCTION
Drug development efforts have shifted from physiology and natural product
driven strategies to target-based drug discovery (1) in recent years. Combinato-
rial chemistry, high throughput and high content screening (HTS/HCS), mRNA
expression arrays, proteomics or systems biological approaches to name only
some of the directions of research have, however, not fulfilled the expectations
for the identification of substantial numbers of new targets and lead structures
(2,3). It is presently suggested to remember earlier strategies as useful and ne-
cessary complements to target-based drug discovery (2-6). 
The cause for the limited success is in all likelihood not due to the incapa-
city of the new technologies but amongst various reasons, like the multitude of
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possibilities for combining the various approaches (3), primarily to the relative
lack of knowledge on the relevant molecular processes in complex human di-
seases. Such knowledge represents a necessary precondition to mimic the in-
vivo human disease situation as perfect as possible by disease-relevant models
like for example molecular systems, single or mixed type cell cultures, ex-vivo
tissue samples or research animal models. 
It is the purpose of this contribution to show how the knowledge on molecu-
lar processes in complex human diseases can be substantially increased by single
cell oriented multiparametric analysis of aberrant molecular cell phenotypes in di-
sease associated cell systems of individual patients. This exploration strategy re-
presents an essential feature in the context of a suggested human cytome project. 
2. GROUP OR INDIVIDUALIZED ORIENTATION?
Individuals are heterogeneous for their genetic background as well as for
their cumulated exposure to the many permanently existing external influences.
Further heterogeneity exists in the specialized organs or tissues, each consisting
of multiple cell types of significant internal heterogeneity, for example accor-
ding to cell cycle, functional status, size and molecule content. 
The observed multiparametric cellular and molecular heterogeneity prompts for
a simplified evaluation of patients as groups to obtain average molecular informa-
tion. Group oriented Kaplan-Meier statistics (7,8) are for example frequently used
during therapy development to stratify patient groups according to their behavior
according to various combinations of molecular or clinical parameters. Hierarchical
clustering (9) as another example characterizes similarly expressed groups of gene
products at the mRNA level. Although informative as a trend, there is the inherent
problem that only a certain proportion of patients in this averaged heterogeneity will
respond to a given therapy or show the average gene expression profile. 
It is for example not possible to predict the therapy response of individual pa-
tients on the basis of group oriented evaluations. There is, however, significant cli-
nical interest in the future disease course of individuals in stratified patient groups to
optimize therapy and to minimize irreversible tissue damage by the disease process
or by adverse drug reactions. This means for example to predict the therapeutic be-
nefit on a person to person basis prior to the start of therapy and to individually se-
lect the most appropriate therapy amongst several possible therapeutic options in a
given situation. It seems furthermore important to explore the molecular causes for
the lack of response to therapy in an individualized/personalized fashion. 
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This may seem at first glance impossible considering the many existing he-
terogeneities. But individualized predictions can be obtained when investigating
the molecular heterogeneity at the single cell level using a differential biopara-
meter pattern approach to characterize the disease induced aberrant molecular
cell phenotypes (10). Molecular cell phenotype analysis can be performed by
high-throughput image (11,12) or flow cytometric (13) analysis. 
3. SINGLE CELL ANALYSIS
3.1. Why single cell analysis?
Considering the high number of possibilities for investigating gene activa-
tion or proteomics array patterns, metabolic pathways, metabolite panels, cell
organelles, cells or tissues it may be asked why molecular single cell analysis
is the preferred aim.
The reason for this is that cells represent the elementary building units of
cell systems, organs and organisms and diseases are caused by molecular chan-
ges in cells and cell systems. Single cell analysis by molecular content as in flow
cytometry (14) or by molecular morphology as in image cytometry (12) provi-
des a maximum of compartmentalized molecular heterogeneity. This assures a
maximum of resolution to discriminate for example the molecular changes in di-
seased or disease associated cells from those in non affected bystander cells.
Technical progress permits detailed single cell analysis by chemical cyto-
metry using microfluidic chips (15,16) or capillary electrophoresis (17,18). Cell
microgenomics expression profiles (19) as well as single cell proteomics (17)
and metabolomics (15,16,18) become accessible in this way. 
Single cell techniques overcome the problem of averaged cellular informa-
tion from cell homogenates or extracts where it cannot be decided whether ob-
served changes derive from all cells or only from a particular cell subpopulation. 
The analysis of humoral body compartments like blood plasma or serum,
urine or cerebrospinal fluid as an alternative provides secondary information on
cell derived molecules. Metabolites from cellular disease processes may have
been altered in the meantime or they may not become apparent in humoral com-
partments for lack of secretion or fast renal or biliary excretion. As a conse-
quence, important information may not be measurable at the secondary com-
partment level although significant advances in metabolite profiling have been
reached (20). 
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3.2. Representative single cell sampling
Although multiparametric molecular single cell analysis is desirable for con-
ceptual reasons, one may object that the single cell approach will frequently not
be feasible since not all cells of a given sample can be analyzed like for exam-
ple in smears, biopsies or histological sections. This is, however, not necessary
as long as a representative number of disease associated cells with aberrant mo-
lecular cell phenotype can be analyzed together with some non affected refe-
rence cells as shown by the subsequent examples. 
Mechanical disaggregation of tissues at 0-4ºC for cell function analysis by flow
cytometry destroys between 90-95% or more of all cells. Mechanical preparation
is preferable since enzymatic cell preparation at 37ºC as an alternative generates a
similar degree of destruction but, in addition, may alter the metabolic condition of
relevant cells during the incubation time as well as enzymatically modify cell mem-
brane parameters. Both procedures lead to an enrichment of epithelial and inflam-
matory cells since fibroblasts or smooth muscle cells are mostly destroyed during
cell preparation. Despite this, more than 90% of lung and colorectal cancer patients
are correctly identified from flow cytometrically determined molecular cell pro-
perties (21,22). This indicates that representative fractions of surviving cancer cells
and normal epithelial or inflammatory cells as reference are sufficient for the iden-
tification of cancer patients although the cellular composition of the samples has
changed and tissue architecture was lost during cell preparation. 
The result is not surprising since diseases represent molecular changes in cells
and cell systems. The analysis of diseased cells or of disease associated inflam-
matory and immune cells contains therefore by itself enough molecular informa-
tion about the actual state (diagnosis) and the future development (prediction) of a
disease. The correct sample classification is in these conditions to a sufficient de-
gree independent of the original location of the analyzed cells in a tissue and equally
of the representative presence of all initial types of organ cells. This applies in all
likelihood equally to image analysis where it may for example not be necessary to
contour all nucleated single cells in a given sample to obtain discriminatory infor-
mation, especially in cases where cell boundaries are difficult to detect. 
A further reservation concerning single cell analysis is that cell properties
may be altered during preparation for analysis (23). Cell preparation between 0-
4ºC for functional studies, deep-freezing of tissues or immediate cell fixation
minimizes, however, such risks. 
Valuable information is for example obtained from the functional analysis of
oxidative status or oxidative burst in viable ex-vivo immune cells like lympho-,
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mono- and granulocytes despite the high susceptibility of these cells to external
influences. Disease associated cells can be measured in tissues but advantageously
also frequently in the peripheral blood where high speed multiparameter flow cyto-
metric single cell analysis is possible and provides individualized predictions or
risk assessments for example in intensive care medicine (24,25). 
As a conclusion, molecular alterations by cell preparation or staining steps
cannot be generally entirely excluded. Keeping the cells, however, close to the
in-vivo conditions during removal and short term storage or until fixation, the
determination of clinically relevant molecular cell parameters for patient care
and research purposes is definitely not impaired. 
4. DIAGNOSIS AND PREDICTIVE MEDICINE
Diseases are typically diagnosed by clinicians from clinical symptoms, al-
tered clinical chemistry parameters or by the pathologists evaluating the mi-
croscopic morphology in tissue sections or in cytological specimens. 
Single cell image or flow-cytometric analysis extends the diagnostic knowled-
ge level by the determination of differential bioparameter patterns (10). Alterations
may be recognized at a stage where no morphological correlate is yet detectable.
The multiparametric measurements of molecular cell phenotypes address the pre-
diction of the therapy-related future disease course of individual patients as a clini-
cally promising new feature of the predictive medicine by cytomics concept (10,25). 
5. BIOINFORMATIC DATA EVALUATION
5.1. Cytomics
Multiparametric single cell analysis by flow or image cytometry can provide sig-
nificant amounts of data that may seem difficult to analyze (23). Differential data pat-
tern classification (26) provides the means to analyze multitudes of multiparametric
data like ~0.5-1x105 data columns or more at a time. Data of various types like from
flow and image analysis, chip arrays, clinical chemistry and clinical provenience can
be merged and simultaneously processed like in the context of predictive medicine by
cytomics (10). Cytomics is defined as multimolecular cytometric analysis of cell and
cell system heterogeneity in combination with exhaustive bioinformatic knowledge
extraction from all measured cells (27). Highly discriminatory bioparameter patterns
can be obtained by algorithmic data analysis comprising typically between 10 and 30
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parameters. The bioparameter patterns can be used for further scientific analysis. Sin-
gle cell and single individuum oriented analysis provide in this way a maximum of
discrimination since no averaging over heterogeneous entities occurs during data ac-
quisition and bioinformatic evaluation. Once the individualized information has been
obtained, group directed analysis can be performed at a maximum level of resolution.
5.2. Data pattern classification
Data pattern classification represents an algorithmic data sieving procedu-
re for the individualized analysis of multiparametric data. The goal of the analy-
sis concerns i) the determination of the most discriminatory bioparameter pat-
terns between several patient categories being characterized in a multiparametric
way and furthermore ii) the therapy related disease course predictions in indi-
vidual patients with an accuracy >95% as belonging to one of the categories.
The 95% level represents a first approximation. It seems possible to reach 99%
or even higher levels when more multiparametric molecular single cell kno-
wledge in disease will become available with time.
The classification process is automated and does not require personal interfe-
rence once initiated. The principle of data pattern classification consists in the trans-
formation of numerical data column values into the triple matrix characters (—)=
decreased, (0)= unchanged and (+)= increased, followed by the iterative elimina-
tion of non-discriminatory data columns. Individual patients are classified accor-
ding to the highest positional coincidence between their patient classification mask
and any one of the disease classification masks (table 1). The classification prin-
ciple assures high classification accuracy at high multiplicity of patient classifica-
tion masks to account for the many combinatorial possibilities between genotypic
and exposure influences on the selected discriminatory parameters. The patient clas-
sification masks can be further analyzed for similarities and dissimilarities in an ef-
fort to systematically investigate genotypic and exposure influences on patients with
complex diseases such as infections, diabetes, rheumatic diseases, allergies, asthma,
atherosclerosis, myocardial infarction, malignancies and others.
5.3. Classification of multiparametric patient data
The numerical values for the subsequent classification are localized in da-
tabases (table 2) (28,29). The databases classified here derive from an earlier
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study on the identification of angiographically defined myocardial infarction risk
patients from surface antigen patterns of circulating and partially activated pe-
ripheral blood thrombocytes (28). The data column values in the databases can
be either directly measured or calculated from multiparametric single cell flow
or image cytometric measurements. Merged databases containing numerical re-
sults from various types of measurements can be jointly classified. 
Prior to the classification, the available data are divided into a learning set
of patients and into an unknown test (validation) set remaining inaccessible to
the learning process. Typically, patients 1,5,10,15,20 etc of each classification
category are a-priori assigned to the unknown test set. In this way it is assured
that the data of this embedded test set are objectively selected and representa-
tive for the learning set since they have been collected under similar conditions. 
An upper and lower percentile is now calculated for the reference category
patients or samples of each available data column (figure 1). The reference cate-
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TABLE 1. Classification Principle of the CLASSIF1 Algorithm
A.) disease classification masks 
(schematic for 10 parameters) disease course prediction
0000000000 stationary
++++++++++ improvement
————— deterioration
B) patient classification masks
(some examples)
0+000-00+0 stationary
00+-00+-00 stationary
++000-0+0- stationary
0-0—+000- stationary
+-0000-0+0 stationary
++0-0++0+0 improvement
-0-0-+-0+- deterioration
... ...
patient classification: highest positional coincidence between patient classification mask and any one of the
disease classification masks
characteristic features of data pattern classification:
high accuracy at low risk of random coincidence between patient and disease classification mask. Probabi-
lity is 0.0017% (1/310 ) for random coincidence with 10 parameter masks and 0.046% (1/37 ) for 7 parameter
masks.
high multiplicity of patient classification masks at correct classification in case of partial positional coinci-
dence like 7 out of 10 parameters:
10! x 23 = 960 possible patient classification masks as potential result of genotype
7! x 3! and exposure influences on the molecular cell phenotype or other para-meters.
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FIGURE 1. Calculation of lower and upper percentile thresholds for the value distribution of each
data column of the reference group of patients. In reality the percentile thresholds 1, 2, 5, 10, 15,
20, 25, 30, 70, 75, 80, 85, 90, 95, 98 and 99% are calculated. This permits to find the optimally
discriminating percentile thresholds for the transformation of the numerical data column values
into triple matrix characters during the subsequent iterative optimisation procedure. 
TABLE 2. CD62 Database parameters
nr parameters
1 %CD62 positive thrombocytes
2 thrombocyte mean FSC
3 thrombocyte mean SSC
4 thrombocyte mean ratio SSC/FSC
5 mean CD62 on all thrombocytes
6 mean CD62 on CD62 positive thrombocytes
7 mean CD62 on CD62 negative thrombocytes
8 mean CD62 surface density on all thrombocytes
9 mean CD62 surface density on CD62 positive thrombocytes
10 mean CD62 surface density on CD62 negative thrombocytes
11 % CD62 negative thrombocytes
Four databases containing a total of 4x11 parameters for CD62, CD63 and thrombospondin expression as
well as for immunoglobulin gamma (IgG) binding to thrombocytes of an earlier study (28) were used to
illustrate the principle of data pattern classification. 
gory consists for example of healthy normal individuals but stationary or survi-
vor patients may also serve as reference depending on the purpose of the classi-
fication. Percentiles like the 10% or 90% percentiles represent the threshold va-
lues at which 10% or 90% of the values of a reference category data column are
reached. The calculation is performed in the same way for all data columns. 
Percentile value calculations do not require assumptions regarding the ma-
thematical distribution of data column values for reference or other category pa-
tients. This is advantageous since value distributions from flow or image analy-
sis are frequently not distributed according to standard statistical functions. 
The numerical values for the reference as well as for the non reference pa-
tients are subsequently transformed for each data column into the triple matrix
characters (+) for values above the respective upper percentile, (—) for values
below the respective lower percentile and (0) for values between both percen-
tile thresholds. This yields a triple matrix replica (figure 2) of numerical data-
bases as starting condition for the iterative selection of the discriminatory data
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FIGURE 2. Transformation of numerical data column values into triple matrix characters (—),
(0), (+). Two percentile thresholds are required for the transformation. The numerical values of
each data column that is the values of the reference as well as of the other classification cate-
gories are transformed into the triple matrix characters (—) = diminished, for values below the
lower threshold, (0)= unchanged, for values between the lower and upper threshold and (+) =
increased, for values above the upper threshold. 
columns. Percentile based data classifications perform fast since the iterative
calculations require only value comparisons that represent an elementary func-
tionality of computer processing units. 
Following the triple matrix transformation, the molecular status of each pa-
tient is represented by the patient classification mask consisting of a sequence of
triple matrix characters (+), (—) and (0). The most frequent triple matrix charac-
ter of each data column is placed for each classification category into a disease
classification mask. The disease classification mask for reference patients contains
typically (0) values because for example in the 10-90% percentile condition, (0)
is the most frequently encountered triple matrix character. Its occurrence is 80%
in each data column with additional 10% (+) and 10% (—) characters. 
Data columns with (0) characters in the various classification categories are
immediately removed from the classification process since they do not contain dis-
criminatory information. This leaves 23 of the 44 initial data columns (figure 3).
In a first classification round, patients are classified according to the hig-
hest positional coincidence of their patient classification mask with any one of
the disease classification masks. The classification results are entered into a clas-
sification (confusion) matrix with the present (diagnosis) or future (prediction)
clinical truth typically on the ordinate while the classification results from the
multiparametric data set is displayed on the abscissa (table 3A). Ideally, that is
when the classification from the measured parameters reflects exactly the clini-
cal situation, there will be 100% values on the diagonal of the classification ma-
trix while all other boxes contain 0% values. This is not the case at the initial
classification step. It is now important to determine the discriminatory infor-
mation content of each data column to ultimately enrich a maximum of discri-
minatory capacity within the disease classification masks. 
The discriminatory capacity of each data column is determined by its tem-
porary removal from the classification process, followed by reclassification of
the remaining data columns. Deterioration of the previous classification result
indicates a positive discriminatory capacity of the removed data column while
improvement reveals it as non-discriminatory. The removed data column is sub-
sequently reinserted and the next data column is checked in the same way. Dis-
criminatory data columns are internally labeled with a virtual green stamp whi-
le non-discriminatory columns obtain a virtual red stamp. Only data columns
with green stamps are kept in the final disease classification masks. The «tra-
cer» like temporary removal of individual database columns assures that the dis-
criminatory capacity of the individual data columns is determined against all re-
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maining data columns. The iterative procedure identifies usually most of the data
columns as being non-discriminatory for the classification. 
Only 5 of the initial 44 data columns improve (table 3B) the initial classi-
fication result (table 3A) significantly. The proof that this classification result is
not due to the classification of random statistical aberrations in multiparametric
GÜNTER K. VALET
218
FIGURE 3. Triple matrix database following removal of non informative data columns showing
(0) triple matrix characters for normal individuals and infarction risk patients. Twenty-three of
the original 44 database columns remain after this step. They come from each of the four initial
databases (IgG, CD62, CD63, thrombospondin). The finally selected 5 most discriminatory data 
columns are indicated in boldface characters.
data sets, is provided by the unknown embedded data set (table 3C). It is i) co-
rrectly classified by the selected 5-parameter data pattern (table 4) and ii) there
are statistically significant parameter differences (table 5) between normal indi-
viduals and the angiographically defined risk patients for myocardial infarction. 
5.4. Standardized classifiers
Data pattern classifiers are inherently standardized on the data column me-
ans of the reference groups. Reference groups can be constituted by normal in-
dividuals but also by patients with stationary disease or by survivor patients.
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TABLE 3. Risk Assessment from Peripheral Blood Thrombocyte 
Surface Antigens
A.  Before Optimization B.  After Optimization C.  Unknown Test Set
CLASSIF1 risk status (%)
clinical risk pat infarction pat infarction pat infarction
status (n) normal risk (n) normal risk (n) normal risk
normal 13 100.0 0.0 13 100.0 0.0 4 100.0 0.0
inf.risk 74* 41.9 58.1 77 0.0 100.0 20 0.0 100.0
neg/pos
pred.val — 29.5 100.0 — 100.0 100.0 — 100.0 100.0
4x11=44 data columns CD62,CD63,thrombospondin and bound IgG classified with 10+15+20%
optimized percentile thresholds against the angiographically defined risk status
*) 3 patients show the transitional classification normal/infarction risk. They are not included into the classi-
fication result before optimization. 
Bold numbers on the classification diagonals indicate specificity and sensitivity with negative and positive
predictive values in the bottom line.
TABLE 4. Selected Classification Parameters
nr classification parameters assay N IR
1 IgG on IgG positive thrombocytes FSC/SSC/IgG 0- +
2 CD62 on CD62 positive thrombocytes FSC/SSC/CD62 0- +
3 CD63 mean surface density on CD63 positive thrombocytes FSC/SSC/CD63 0- +
4 thrombospondin (TRSP) on TRSP positive thrombocytes FSC/SSC/TRSP 0- +
5 TRSP mean surface density on TRSAP positive thrombocytes FSC/SSC/TRSP 0- +
FSC= forward light scatter, SSC = sideward light scatter, N=normal, IR= infarction risk
The identity of reference groups between institutions is verified by classifying
the respective reference data sets against each other. In case, reference groups
from different institutions are undistinguishable by data pattern classification,
they can be considered identical for classification purposes. This provides the
potential to merge data between institutions with the aim to enlarge data sets
and to establish public databases. 
When differences during the comparison of reference groups are detected,
they may be due to methodological, compositional like for sex or age, ethnic or
exposure differences of the included individuals. 
5.5. No artifactual misclassification of random number data sets
It is important to investigate the susceptibility of data pattern classification
to the artifactual classification of random statistical aberrations in multiparame-
tric data sets. 
A random number data set of 133 data columns was classified for this purpose.
The data set consisted of 40 data records. Every second record was a-priori assigned
to either category#1 or category#2 yielding 20 data records of either type. The coeffi-
cients of variation (CV=100*standard deviation/mean) of the data columns varied bet-
ween 0.97-25.7%. Data records 1,5,10,15 and 20 of each category were a-priori assig-
ned to the unknown embedded test set, leaving a learning set of 15 category#1 and 15
category#2 records. The classification of all data columns (table 6A) indicated no dif-
ference between category#1 and category#2 records. The automated iterative removal
of 130 non informative data columns resulted in 3 data columns providing a certain de-
gree of discrimination between category#1 and category#2 records (table 6B). The clas-
sification is, however, not informative because (i) the classification of the unknown test
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TABLE 5. Numerical Characteristics of Selected Thrombocyte Parameters
normal infarction risk statistical selected lower & standardized
parameter means±SEM means±SEM significance upper percentiles percentiles
(AU*, n=13) (AU*, n=77) (Student P %) (AU*) (perc/mean)
IgG on IgGpos 13.6±0.1 16.7±0.2 < 0.001 12.9/13.9(10/90%) 0.95/1.02
CD62 on CD62pos 14.3±0.4 19.0±0.2 < 0.001 13.4/14.7(15/85%) 0.94/1.03
CD62 SURFD on CD63pos 1.49±0.03 1.77±0.03 < 0.001 1.34/1.60(10-90%) 0.90/1.07
TRSP on TRSPpos 14.1±0.2 20.3±0.2 < 0.001 13.4/14.8(10-90%) 0.95/1.05
TRSP SURFD on TRSPpos 1.55±0.94 2.46±0.06 < 0.001 1.33/1.71(10-90%) 0.86/1.10
* AU = arbitrary units, IgG=immunoglobulin gamma, SURFD=mean surface density
set is insufficient (table 6C) and (ii) the selected data columns are not statistically dif-
ferent between the two categories (col29: 73.2±6.6/72.8±11.1, col77:
53.3±8.0/58.9±11.3, col133: 24.9±3.7/24.9±5.8, means±standard deviation). 
The classification result indicates robustness of the triple matrix data pat-
tern classifier against the artifactual interpretation of random statistical aberra-
tions as real differences. 
6. HUMAN CYTOME PROJECT AND DRUG DISCOVERY
6.1. Bioparameter patterns
The determination of individually predictive bioparameter patterns by data
pattern classification opens a way to the i) reverse engineering of molecular cau-
ses inducing favorable or unfavorable bioparameter patterns and ii) to the dis-
covery of new drug targets. 
The initial selection of the investigated multiparameter parameters in a gi-
ven situation is hypothesis driven and varies from investigator to investigator.
The cytomics data analysis, in contrast, is hypothesis free because it effectuates
the exhaustive differential knowledge extraction from all analyzed cells or other
data. This opens the way for the detection of so far unknown molecular me-
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TABLE 6. Classification of Random Number Dataset
A.  Before Optimization B.  After Optimization C.  Unknown Test Set
CLASSIF1 category (%)
assigned rec rec rec
category (n) cat#1 cat#2 (n) cat#1 cat#2 (n) cat#1 cat#2
cat#1 15 100.0 0.0 15 100.0 0.0 5 33.7 66.7
cat#2 15 100.0 0.0 15 60.0 40.0 5 80.0 20.0
neg/pos
pred.val — 50.0 0.0 — 62.5 100.0 — 33.5 25.0
Category#1 records are indistinguishable from category#2 records when all data columns are classified toge-
ther (A), while a certain degree of discrimination is obtained after removal of 130 non discriminatory data
columns (B). The classification quality for the unknown test set (C) is insufficient. It is based on differences
of the 3 selected data columns. The differences are statistically not significant between the two classification
categories. This indicates the robustness of the CLASSIF1 algorithm against the artifactual interpretation of
random statistical aberrations as real differences. The data records were classified using the optimal percen-
tile thresholds 15% and 85%. Bold numbers are as in tab. 3.
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FIGURE 4. Reclassification of the learning set. The first ten patients of either classification ca-
tegory are displayed. All patients are correctly classified according to the highest positional coin-
cidence of the patient classification mask with any one of the disease classification masks. The
mask coincidence factor indicates the degree of positional coincidence between the patient clas-
sification mask and the selected disease classification mask. In some instances the mask coinci-
dence factor is 1.00 (arrows) despite the fact that not all characters of the disease classification
mask are (0) for reference patients. Since infarction risk show increases (+) for the five selected
data columns, unchanged (0) as well as decreased (-) values indicate normal individuals. Patients
#101, 105, 110, 136, 140, 145 are missing in the table because they had been a-priori assigned 
to the unknown test (validation) set. 
chanisms or of the action of particular regulatory networks in heterogeneous cell
systems remaining typically hidden to the global analysis of tissues or biopsies
and as a consequence also to hypothesis driven approaches. 
In the course of cytomics studies, new drug targets may be recognized by
multiparametric single cell oriented tissue (11) or high throughput (30) cell
analysis. The analysis may also provide the relevant information for a particu-
lar in-vitro composition of disease-relevant complex human cell systems (31)
mimicking the molecular in-vivo behavior of defined patient groups in disease. 
6.2. Systems biology
The suggested molecular reverse engineering of the observed discrimina-
tory bioparameter patterns prompts for the subsequent mathematic modeling of
molecular disease pathways as one of the preconditions for the rational unders-
tanding of complex disease processes in man. 
Systems biology aims at the understanding of the integral functionality of
single cells, organs or organisms by molecular analysis and mathematical mo-
deling using controlled perturbations for the differential screening of molecular
changes induced at different levels (23,32-35). This task is significantly more
complex for organisms than for single cell systems like for example bacteria or
yeast. The prediction of the reactivity of biological systems under predefined
conditions, represents an important further goal of systems biology. Predictions
should be indeed feasible, once a majority of possible reactivities in a biologi-
cal system have been explored by differential perturbations.
6.3. High complexity by bottom-up 
Numerous perturbations may, however, be required to describe major mole-
cular pathways by hypothesis driven bottom-up analysis from the genome level
via the proteome, the metabolome (27), the organelle compartments up to the le-
vel of cells, cell systems, organs and organisms (36). This is especially true when
considering the high number of potential interrelations amongst 30.000 to 40.000
human genes as well as the cellular complexity of tissues and organs. 
It is unknown, how much molecular knowledge is necessary to predict for
example the disease susceptibility or future disease course in individual patients.
It may also be impossible to obtain sufficient information by systematic bottom-
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up forward engineering of mammalian organisms within reasonable time inter-
vals, seen the complexity of the entire system. 
As an alternative, cell cultures, or diseased as well as genetically modi-
fied animals, may be used as model systems for human disease. Significant
concerns as to the ultimate validity of the conclusions from such model
systems for the human in-vivo situation, especially in disease or in the se-
arch for new drug targets, have, however, been raised (37). Cell or animal
model systems may frequently not permit to generate valid mathematical mo-
dels of the human organism by systems biology especially if there is insuf-
ficient information on the heterogeneous single cell complexity of diseased
human tissues.
6.4. Top-down in the proposed human cytome project 
In this situation, a top-down research strategy simplifies the task. Nature
induced bioparameter perturbations or differentials such as between diseased
versus healthy, progressive versus stationary disease or survivor versus non-
survivor patients can be directly analyzed instead of generating hypothesis dri-
ven systematic perturbations in model systems. Individualized disease course
prediction for patients are possible in this way (10) without prerequisite to a-
priori fully understand the entire molecular network of disease associated cell
system changes. Discriminatory bioparameter patterns are obtained by multi-
parameter data analysis as described above. These patterns can be further in-
vestigated by a molecular reverse engineering strategy (38) to understand di-
sease inducing molecular pathways and to find new drug targets (figure 5). It
is advantageous for this biomedical cell systems biology concept (39, 40) that
many in all likelihood suitable data sets are already available as starting mate-
rial from current or past clinical studies where patients are routinely followed
for diagnostic or therapeutic purposes. Further multiparameter data are conti-
nuously being produced in the clinical and medical environment. The concept
of the human cytome project fits furthermore within the top-down approach of
the physiome project (41).
Initial clinical areas suitable for a human cytome project concern the indivi-
dually predictive molecular disease course characterization of leukemia/lympho-
mas, cancers, rheumatoid diseases, allergies and infections, while stem cell diffe-
rentiation, cell cycle regulation, cell proteomics and cell organelle functionality
represent initial areas of interest for basic research. 
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7. CONCLUSIONS
The value of the single cell, single individual analysis concept resides in its
clinical significance for the individual patient as well as in the bioparameter pat-
terns being of interest for i) molecular reverse engineering of molecular disea-
se pathways by systems biology and for ii) the discovery of new drug targets. 
The research concept for the proposed human cytome project is deductive
for the initially selected analytical parameters but inductive during the bioin-
formatic data evaluation phase. It is therefore capable of accessing new kno-
wledge being unreachable by traditional hypothesis formulation. Most of the in-
itially available multiparametric molecular information is typically eliminated
as irrelevant during the algorithmic data-sieving phase, leaving typically a bio-
parameter pattern of between 10 to 30 discriminatory parameters for further
analysis. This provides comparatively simple starting points for retrograde analy-
sis and mathematical modeling efforts by systems biology. 
There is also the possibility of consecutive cyclic knowledge enrichment
steps. The information of the preceding sieving step is used to conceptualize and
perform a new round of multiparametric molecular measurements at the single
cell level to provide the information input for the next data sieving step. 
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FIGURE 5. Concept of the human cytome project
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